Announcement Lumenis Be. Ltd, a pioneering energy-related medical device company, has entered the healthcare market with its new edition of its breakthrough multi-application aesthetic platform, the Stellar M22™, equipped with XPL™ Technology, sponsored by four comprehensive technologie...
Announcement HCW Biologics Inc., a US-based clinical-level biopharmaceutical company aimed at establishing and exploring new innovative immunotherapies to expand healthspan by focusing on the connection between chronic disease and inflammation, proudly declared its dosage completion on the first p...
Announcement Emulate, Inc., a known provider of next-generation Organ-on-a-Chip technology, in collaboration with FUJIFILM Cellular Dynamics Inc., a leading global manufacturer and creator of human induced pluripotent stem cells (iPSCs), has introduced the Emulate Brain-Chip R1. The first-ever and...
Announcement Hemostemix Inc., a known champion in regenerative medicine, will be at the Innovations in Wound Care Conference in Key West, Florida, scheduled from December 11-14, 2025. The company will flaunt its world-class angiogenic cell therapy, ACP-01. The therapy, which heals ulcers, reduces ...
Announcement Medexus Pharmaceuticals has joined hands with the National Bank of Canada as an administrative agent under the new senior secured credit agreement. This new credit agreement will deliver US$21.0 million term loan facility and a revolving loan facility worth US$5.0. The term loan facili...
Announcement Augurex Life Sciences Corp., a key player in the establishment of autoimmune-related diagnostics, have introduced its upcoming 14-3-3eta test to soon ramp the official stage. The 14-3-3eta test is approved as JOINTstat® in the UK and Canada and came into recognition via Sonic Refer...
Announcement Eli Lilly's back-to-back acquisitions are making headlines, and now the company has signed one more cheque to purchase South Korea’s ABL Bio to gain access to reliable technology and bolster and expand its pipeline. Neither company has disclosed their planning for the programs t...
Announcement Where Halda Therapeutics is establishing oral assets for lung and prostate cancer, the strategic deal offer from Johnson & Johnson, with its dedicated mission for its cancer sales by 2030, brings new hope for both companies for growth, business and development. Johnson & Johns...
Announcement Repare Therapeutics Inc., a clinical-level precision oncology company, has inked the definitive agreement with Xeno Therapeutics Inc. and Xeno Acquisition Corp., a non-profit biotechnology company. Under this definitive agreement, Xeno will obtain each outstanding and issued common sh...
Announcement The Indian government came ahead with the new transformation in the medical tourism landscape by announcing a transitional visa-on-arrival policy for the US and European travellers to make the reach of the best-in-class wellness retreats and health treatments more hassle-free in every...
